MorphoSys AG (WBO:MOR)
€ 67.6 0.8 (1.2%) Market Cap: 2.53 Bil Enterprise Value: 2.49 Bil PE Ratio: 0 PB Ratio: 52.00 GF Score: 59/100

MorphoSys AG at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 11:00PM GMT
Release Date Price: €36.71
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Great. Good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech Analyst. And today, I've got the pleasure of introducing the MorphoSys presentation. And you're going to hear from MorphoSys CEO Jean-Paul Kress.

Thanks very much for joining us today. Looking forward to the presentation.

Jean;Paul Kress
MorphoSys AG - Chairman of Management Board, MD & CEO

Thank you, James. Thanks for having me and very pleased to share with you the great progress we're making at MorphoSys. Please have a look at our forward-looking statement slide.

A few years ago, we redefined the strategy of the company, and we centered on oncology and more specifically, hematology oncology. And for that, we beefed up our pipeline with the acquisition of Constellation and mainly pelabresib, which is our number one opportunity. Pelabresib is a BET inhibitor, which has the potential to redefine the standard of care in myelofibrosis first line and establish a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot